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ORIGINAL INVESTIGATION
Delay in treatment intensification 
increases the risks of cardiovascular events 
in patients with type 2 diabetes
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Abstract 
Background: The aim of the study was to evaluate the effect of delay in treatment intensification (IT; clinical inertia) 
in conjunction with glycaemic burden on the risk of macrovascular events (CVE) in type 2 diabetes (T2DM) patients.
Methods: A retrospective cohort study was carried out using United Kingdom Clinical Practice Research Datalink, 
including T2DM patients diagnosed from 1990 with follow-up data available until 2012.
Results: In the cohort of 105,477 patients mean HbA1c was 8.1% (65 mmol/mol) at diagnosis, 11% had a history of 
cardiovascular disease, and 7.1% experienced at least one CVE during 5.3 years of median follow-up. In patients with 
HbA1c consistently above 7/7.5% (53/58 mmol/mol, n = 23,101/11,281) during 2 years post diagnosis, 26/22% never 
received any IT. Compared to patients with HbA1c <7% (<53 mmol/mol), in patients with HbA1c ≥7% (≥53 mmol/
mol), a 1 year delay in receiving IT was associated with significantly increased risk of MI, stroke, HF and composite CVE 
by 67% (HR CI: 1.39, 2.01), 51% (HR CI: 1.25, 1.83), 64% (HR CI: 1.40, 1.91) and 62% (HR CI: 1.46, 1.80) respectively. One 
year delay in IT in interaction with HbA1c above 7.5% (58 mmol/mol) was also associated with similar increased risk of 
CVE.
Conclusions: Among patients with newly diagnosed T2DM, 22% remained under poor glycaemic control over 
2 years, and 26% never received IT. Delay in IT by 1 year in conjunction with poor glycaemic control significantly 
increased the risk of MI, HF, stroke and composite CVE.
Keywords: Type 2 diabetes, Delay in treatment intensification, Cardiovascular risk, Longitudinal analysis, Clinical 
inertia
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Background
Currently 8.3% of adults worldwide are estimated to have 
diabetes [1]. The risk of cardiovascular complications 
has been related to glycaemia in patients with type 2 
diabetes mellitus (T2DM). Randomised controlled trials 
have conclusively demonstrated that the risk of micro-
vascular complications can be reduced by intensive gly-
caemic control in patients with T2DM [2–4]. However, 
there are controversies regarding the benefits of inten-
sive glucose control [HbA1c <7% (53  mmol/mol)] on 
macrovascular events (CVE), as some of the large trials 
have failed to show any significant reduction in CVE [4, 
5]. The ACCORD trial failed to show any benefit of inten-
sive glucose lowering on CVE, although the haemoglobin 
A1c (HbA1c) level was reduced to 6.4% (46.4 mmol/mol) 
in the intensive treatment arm compared to HbA1c level 
of 7.5% (58.5 mmol/mol) in the standard treatment arm 
[6]. The primary care based randomised trial ADDITION 
reported only a small, non-significant reduction in the 
incidence of CVE and death associated with early inten-
sive management of the disease [7]. However, the UKPDS 
Post Trial Monitoring Study demonstrated that intensive 
glucose control starting at the time of diagnosis of dia-
betes could be associated with a significantly decreased 
risk of myocardial infarction (MI) and death from any 
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cause [8]. Also, the meta-analysis of four large cardiovas-
cular outcome trials in patients with T2DM revealed that 
tighter glycaemic control was associated with 9% reduc-
tion in risk of major cardiovascular events [9]. However, 
tight glycaemic control was not associated with reduced 
mortality.
Glycaemic management in patients with T2DM has 
become increasingly complex, and in some cases contro-
versial, with a widening classes of pharmacological agents 
now available [10–12]. Based on the individual character-
istics of the patients, step-wise life-style and pharmaco-
logical approaches have been suggested by international 
guidelines for better glycaemic management in patients 
with T2DM [13–15].
The American Diabetes Association guidelines rec-
ommend starting metformin alongside lifestyle modi-
fications at diagnosis, aiming for a HbA1c target of <7% 
(<53 mmol/mol) [15]. Additional oral anti-diabetes drugs 
(OADs) may be added if the HbA1c continues to remain 
above the recommended target of 6.5% (48  mmol/mol), 
and if HbA1c reaches ≥7.5% (≥58  mmol/mol), further 
intensification including the use of insulin is recom-
mended [13, 16]. The intensification of anti-diabetes 
therapies also depends on individual patient’s charac-
teristics including age, co-morbidities, the risk of hypo-
glycaemia, and provider and patient’s preferences [13]. 
However, a high proportion of people with T2DM fail to 
reach the recommended glycaemic targets for a consid-
erable period of time post diagnosis of diabetes (glycae-
mic burden) [17–21]. Among those with poor glycaemic 
control [HbA1c ≥7% (≥53  mmol/mol)], an overwhelm-
ingly large proportion of people do not receive intensified 
treatment in time. This “delay in treatment intensifica-
tion”, also termed as clinical inertia, has been discussed 
by some studies [17–21]. A recent study based on 80,000 
patients with T2DM from the United Kingdom primary 
care system reported that the average time to intensifi-
cation to two oral anti-diabetes drugs (OADs) from one 
OAD among patients with HbA1c above 7% (53  mmol/
mol) was about 3  years [21]. The aspects of glycaemic 
variability and treatment quality indicators and their 
association with macrovascular risk were evaluated by 
Penno et al. [22] and Sidorenkov et al. [23], respectively. 
Asche et al. [24] evaluated the clinical and economic ben-
efits of early intensification of treatment with insulin in 
patients with T2DM, and reported significant benefits in 
terms of glycaemic management.
While studies have reported the real-world scenario in 
terms of intensification of treatments for hyperglycae-
mia among patients with poorly controlled glycaemia, 
the possible effect of delay in treatment intensification in 
conjunction with the dynamic changes in glycaemic con-
trol on the vascular risk factors, has not yet been studied 
to the best of our knowledge. The aims of this retrospec-
tive cohort study were to (1) explore the glycaemic con-
trol over 2 years post diagnosis of diabetes in relation to 
treatment intensification, and (2) evaluate the effect of 
the delay in treatment intensification in conjunction with 
guideline recommended glycaemic control on the of risk 




The data for this retrospective cohort study was extracted 
from the United Kingdom Clinical Practice Research 
Datalink (CPRD), which is representative of the United 
Kingdom general population [25–27]. All information 
collected in the CPRD has been subjected to validation 
studies and been proven to contain consistent and high-
quality data [26, 28].
Data were extracted from CPRD with a first identifiable 
record of diagnosis code for T2DM covering period from 
January 1990 with follow-up data to December 2012, with 
maximum possible follow-up time of 23 years. The con-
firmation for the incident diagnosis of T2DM was based 
on Read/Oxford Medical Information System Codes [29], 
supported by rigorous classification techniques [30, 31].
The following information was extracted: age, gender, 
smoking status (defined as current, ex or never smoker), 
body mass index (BMI), HbA1c, history of cardiovascular 
and renal diseases before the diagnosis of diabetes, and 
clinical events during follow-up, including cardiovascu-
lar diseases (MI, HF, stroke and coronary heart diseases), 
atherosclerosis, diabetic neuropathy, and renal complica-
tions, along with dates of events. Detailed information 
on OADs and insulin along with anti-hypertensive and 
cardio-protective medications (including use of ACE 
inhibitor, Beta Blocker, Statin and other concomitant 
medications) were obtained from prescriptions along 
with dates. The study cohort (n  =  105,477) was based 
under the conditions: (1) read code for T2DM and at least 
two prescriptions for any OAD or insulin (as recorded 
in the primary care system) within 6  months of date of 
diagnosis of T2DM (prescription provided and recorded 
by general practice), (2) age ≥18 years at index date (date 
of diagnosis of T2DM), (3) complete information on 
age, sex, smoking status at index date, (4) a measure of 
HbA1c available within a 3-month window of the index 
date (HbA1c measured within 3 months before the date 
of first diagnosis code recorded), (5) minimum 2 years of 
follow-up before the occurrence of any CVE post diag-
nosis of diabetes, (6) availability of dates of prescriptions 
longitudinally for anti-diabetes drugs, (7) completeness 
of dates for all CVEs during post diagnosis follow-up. 
Choice of this cohort of patients with new diagnosis of 
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T2DM ensures censoring for CVE in the first 2 years post 
diagnosis of diabetes, and 2 years window for treatment 
intensification with the availability of data on glycaemic 
control.
Clinical comorbidities prior to diagnosis of diabetes, 
including cardiovascular and renal diseases, were coded 
as present if they were diagnosed at any point between 
entry into CPRD and the index date. The clinical and 
laboratory measures were arranged longitudinally on the 
basis of 6-monthly windows. The 6-month windows were 
defined progressive from the index date, with 180  days 
immediately post index date defining first follow-up 
window.
The study was approved by the Independent Scientific 
Advisory Committee (Protocol no 13_062R2).
Statistical methods
Treatment intensification (IT) was defined in two ways: 
(1) adding a second OAD (OAD2) or (2) adding insulin 
to the first OAD (OAD + INS). Time to IT was calculated 
by subtracting the index date from the first date of IT. 
The subjects who did not belong to OAD2 or OAD + INS 
groups were defined as “never intensified” category.
Missing HbA1c data (about 9% missing over 24 months 
post diagnosis) at 6-monthly window were imputed 
using multiple imputation technique (Bayesian MCMC 
approach) [32, 33]. The consistency of the imputed data 
with the original HbA1c data was verified. Adequate 
checks were in place to ensure that patients were not lost 
to follow-up for imputing missing values during 2 years 
post diagnosis. Patients were categorized by HbA1c 
below or above 7% (53 mmol/mol) and 7.5% (58 mmol/
mol) consistently over 1 and 2  years post diagnosis to 
identify poor glycaemic control.
The composite CVE was based on the occurrence of 
either of MI, HF or stroke. To evaluate the effect of delay 
in IT on events, only those vascular events were consid-
ered which occurred after the time of first intensification 
(OAD2 or OAD +  INS), apart from the condition of no 
occurrence of CVE during first 2 years post diagnosis of 
diabetes (to ensure minimum exposure time of 2 years). 
In this context, the “time to” individual events were cal-
culated by subtracting the first event date (as appropri-
ate) from the date when intensified treatment started. 
The analysis set for cardiovascular risk analysis included 
only those belonging to OAD2 or OAD + INS categories.
As time to treatment intensification (TTIT) is highly 
likely to be interacted with the glycaemic control over 
time, the interaction of TTIT with HbA1c categories over 
time was evaluated in terms of cardiovascular risks. To 
evaluate the interaction effect we constructed the fol-
lowing four groups: reference group—TTIT <12 months 
and HbA1c <7% (<53 mmol/mol) (consistently <7% over 
12 months post diagnosis); group 1—TTIT ≥12 months 
and HbA1c ≥7% (≥53  mmol/mol); group 2—TTIT 
<12  months and HbA1c ≥7% (≥53  mmol/mol); group 
3—TTIT ≥12 months and HbA1c <7% (<53 mmol/mol). 
The Group 1 reflects both clinical inertia and glycaemic 
burden together, while Group 2 reflects only the glycae-
mic burden. Multivariate Cox regression models were 
used to evaluate the effect of delay in IT in conjunction 
with poor glycaemic control consistently over 1 year post 
diagnosis, adjusting for age and HbA1c at diagnosis of 
diabetes, sex, smoking status, use of cardio-protective 
medications (Statin, ACE/ARB and Beta Blocker), any 
renal disease during follow-up, and the history of CVD 
before diagnosis of diabetes. The proportionality assump-
tion in the models was tested, and stratified models were 
fitted with the quartiles of age at diagnosis of diabetes as 
the stratifying factor. Separate analyses were also con-
ducted for patients with and without the history of CVE. 
Additional multivariate Cox regression models were 
also fitted with incomplete information on BMI, systolic 
blood pressure, LDL-cholesterol and total cholesterol at 
diagnosis (about 62,000 patients).
To evaluate the possible lack of treatment intensifica-
tion in older patients (age >70 years at diagnosis of dia-
betes) and in patients with history of CVD and renal 
diseases, logistic regression models were fitted. The odds 
ratios (OR) and their 95% confidence intervals were pre-
sented. The likelihood of receiving intensified treatment 
in poorly controlled patients by categories based on time 
windows of diagnosis was also evaluated.
Results
In the cohort of 105,477 patients: 56% were male, 62% 
current or ex-smokers, mean (SD) age at diagnosis of 
61 (13) years, and 11% (n = 11,955) had history of CVD 
before the diagnosis of diabetes (Table  1). The distribu-
tion of HbA1c was highly skewed at diagnosis of diabe-
tes, with mean (SD) and median (IQR) levels of 8.1 (2.2)% 
(65  mmol/mol) and 7.4 (6.5, 9.3)% [57 (48, 78) mmol/
mol], respectively, and 62% patients had HbA1c ≥7% 
(≥53 mmol/mol) at diagnosis.
In the study cohort 48,036 patients (46%) received 
intensified treatment (IT) during follow-up. Among 
those who received IT, the proportions with time to IT 
(TTIT) <6  months, <1  year, and <2  years were 26, 36, 
and 53%, respectively. The overall median/mean time 
(months) to receiving IT, at least 2 OADs (2OADs) and 
at least 3 anti-diabetes drugs (3ADDs) were 21/29, 22/29, 
and 43/48, respectively.
The clinical inertia and glycaemic burden
The 6-monthly trajectory of HbA1c over 2  years post 
diagnosis of diabetes, by the categories of TTIT, is 
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presented in Fig. 1. Patients who did not receive any IT 
during follow-up had their average glycaemic level below 
7% (53 mmol/mol) during 2 years post diagnosis, starting 
with an average HbA1c level of 7.4% (57  mmol/mol) at 
diagnosis (Fig. 1a). However, patients who receive inten-
sified treatment continued to have average HbA1c tra-
jectory level around 7.5% (58 mmol/mol) during 2 years 
post diagnosis irrespective of the time of treatment 
intensification (Fig.  1a). Among patients with HbA1c 
≥7% (≥53 mmol/mol) consistently during 1/2 year post 
diagnosis, 29/26% never received any IT during follow-
up. Among those with HbA1c ≥7% (≥53  mmol/mol) 
during 1 year post diagnosis, only 40% received IT before 
12  months, and the median time to IT was 16  months 
(Table  2). In patients with HbA1c ≥7% (≥53  mmol/
mol) consistently during 2 years post diagnosis, only 64% 
patients received IT before 2 years of diagnosis, and the 
median time to IT or receiving at least two OADs was 
17 months (mean = 23 months).
Among patients with HbA1c ≥7.5% (≥58  mmol/mol) 
consistently during 1/2  year post diagnosis, 23/22% 
never received any IT during follow-up. Among those 
with HbA1c ≥7.5% (≥58 mmol/mol) during 1 year post 
diagnosis, only 46% received IT before 1  year, and the 
median time to IT or receiving at least two OADs was 
14  months (mean 20  months). In patients with HbA1c 




Without previous CVD With previous CVD All patients
n 93,522 11,955 105,477
Malea 50,963 (55) 7,609 (64) 58,572 (56)
Age at diagnosis (years)b 60 (13) 68 (11) 61 (13)
Patients by year of diagnosisa
 1990–December 1999 1,893 (2) 201 (2) 2,094 (2)
 January 2000–December 2004 28,551 (31) 3,741 (31) 32,292 (31)
 January 2005–December 2009 52,317 (56) 6,647 (56) 58,964 (56)
 January 2010 10,761 (12) 1,366 (11) 12,127 (12)
Smoking statusa
 Current smoking 17,545 (19) 2,022 (17) 19,567 (19)
 Ex-smoking 39,016 (42) 6,922 (58) 45,938 (44)
BMI at diagnosis (kg/m2)b 32 (7) 31 (6) 32 (7)
HbA1c at diagnosis (%)b 8.2 (2.2) 7.8 (2.0) 8.1 (2.2)
HbA1c at diagnosis (mmol/mol)b 66 62 65
HbA1C ≥7% (≥53 mmol/mol) post diagnosisa
 Consistently during 1 year post diagnosis 27,375 (29) 3,096 (26) 30,471 (29)
 Consistently during 2 years post diagnosis 20,856 (22) 2,245 (19) 23,101 (22)
CVE during follow-upa
 MI 1,876 (2.01) 569 (4.76) 2,445 (2.32)
 HF 2,295 (2.45) 898 (7.51) 3,193 (3.03)
 Stroke 1,782 (1.91) 485 (4.06) 2,267 (2.15)
 Any CVE 4,293 (6.64) 1,833 (8.39) 6,126 (7.08)
Renal diseasea
 Before diagnosis 16,630 (17.78) 3,116 (26.06) 19,746 (18.72)
 Post diagnosis 25,662 (27.44) 4,601 (38.49) 30,263 (28.69)
Duration of follow-up (years)c 5.0 (3.4, 7.2) 5.4 (3.5, 7.7) 5.3 (3.5, 7.7)
Medicationa
 2 OADs 41,696 (45) 4,515 (38) 46,211 (44)
 Insulin 8,778 (9) 1,004 (8) 9,782 (9)
 OAD + insulin 8,380 (9) 954 (8) 9,334 (9)
 Intensified treatment 44,042 (45) 4,012 (56) 48,036 (46)
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≥7.5% (≥58 mmol/mol) consistently during 2 years, 70% 
received IT within 2  years post diagnosis. The median/
mean months to IT and 3 ADDs in this group were 14/20 
and 31/38 months, respectively.
The distribution of patients with diagnosis of diabe-
tes over different time periods from 1990 to 2012 are 
presented in Table  1. The average HbA1c at diagnosis 
in patients who were diagnosed before 2005, between 
2005 and 2009 and from January 2010 onwards were 
8.37, 8.02 and 7.81%, respectively, with similar standard 
deviation of 2.2. Among patients with HbA1c above 7.5% 
(58 mmol/mol) consistently over 1 year post diagnosis of 
diabetes, adjusting for age and baseline HbA1c, patients 
diagnosed between 2005 and 2009 and from January 
2010 onwards were 46% and 139% more likely to receive 
intensified treatment, compared to those who were diag-
nosed prior to January 2000.
Among patients with HbA1c above 7.5% (58  mmol/
mol) consistently for 1  year from diagnosis of diabetes—
patients older than 70 years at diagnosis, with renal disease 
and with cardiovascular disease were 30% (95% CI of odds 
ratio: 0.63, 0.76), 13% (95% CI of odds ratio: 0.79, 0.96) and 
50% (95% CI of odds ratio: 0.45, 0.57) less likely to receive 
intensified treatment during follow-up, respectively.
Effect of clinical inertia on cardiovascular risk
During 5.3  years of median follow-up, the proportions 
of patients who experienced at least one episode of MI, 
Fig. 1 Six-monthly measure of HbA1c (mean and 95% CI) from diagnosis to 2 years, by a patients with and without intensified treatment during 
follow-up, b by patients receiving treatment intensification before or after 12 months of diagnosis.
Table 2 Proportions of  patients with  HbA1c above  7 and  7.5% consistently during  1  year and  2  years post diagnosis 
of  diabetes by  categories of  time to  intensified treatment, and  the median (IQR) months to  treatment intensifications 
from diagnosis of diabetes for various classifications of Hba1c trajectory
n (%) by time to intensified treatment categories Time to intensification median (IQR), months
<6 months <1 year <2 years Time to IT Time to 2 OADs Time to 3 ADDs
HbA1c ≥7% (≥53 mmol/mol)
 Consistently during 1 year 5,768 (27) 8,776 (40) 14,101 (65) 16 (5, 32) 17 (6, 32) 37 (20, 60)
 Consistently during 2 years 4,696 (28) 6,864 (40) 10,904 (64) 17 (5, 31) 17 (6, 32) 36 (20, 58)
HbA1c ≥7.5% (≥58 mmol/mol)
 Consistently during 1 year 3,783 (29) 5,869 (46) 9,284 (72) 14 (5, 26) 14 (5, 27) 33 (18, 54)
 Consistently during 2 years 2,774 (32) 3,999 (46) 6,171 (70) 14 (4, 27) 15 (5, 28) 31 (18, 52)
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stroke, HF, and any of composite CVE were 2.3, 3.0, 2.2 
and 6.8%, respectively. Among those with a history of 
CVD (n =  11,955), these proportions were 4.8, 7.5, 4.1 
and 14.4%, respectively. Patients with HbA1c above 7% 
(53  mmol/mol) consistently during 1  year post diag-
nosis had significantly higher rate (per 1,000 person 
years) of composite CVE [rate (95% CI) for HbA1c ≥7% 
(≥53  mmol/mol) vs <7% (<53  mmol/mol): 1.15 (1.10, 
1.20) vs 1.04 (1.01, 1.08)]. The event rates were similar for 
those with HbA1c ≥7.5% (≥58 mmol/mol) during 1 year 
post diagnosis.
Among all patients, compared to patients with HbA1c 
below 7% (53 mmol/mol) who received IT before 1 year 
of diagnosis, patients with HbA1c ≥7% (≥53 mmol/mol) 
not receiving IT within a year had significantly increased 
risk of MI, HF, stroke and composite CVE significantly by 
67, 64, 51 and 62%, respectively, after adjusting for vari-
ous confounding factors (all p  <  0.01, Table  3). Among 
patients without history of any CVD (n = 93,522), a delay 
in treatment intensification by 12 months [in conjunction 
with poor HbA1c level above 7% (53  mmol/mol)] was 
associated with significantly increased risks for MI, HF, 
stroke and composite CVE by 80% (HR CI: 1.45, 2.22), 
63% (HR CI: 1.36, 1.96), 50% (HR CI: 1.22, 1.84) and 64% 
(HR CI: 1.45, 1.85), respectively (all p  <  0.01). Delay in 
treatment intensification by 12  months in interaction 
with poor HbA1c level above 7.5% (58 mmol/mol) during 
1 year post diagnosis also had similar increased risks for 
CVE. Among patients with history of CVD prior to diag-
nosis of diabetes (n = 11,955), delay in treatment intensi-
fication in conjunction with poor glycaemic control was 
also significantly associated with increased risk of HF and 
composite CVE, but not with MI or stroke (Table 3).
Among patients with HbA1c above 7% (53 mmol/mol) 
consistently during 2  years post diagnosis (n =  23,101), 
patients who did not receive intensified treatment had 
82% (HR CI: 1.67, 2.10) increased risk of composite CVE. 
The risk estimates were similar for patients with and 
without history of cardiovascular diseases. These esti-
mates were obtained after adjusting for all factors men-
tioned in the method section, except any adjustment for 
HbA1c levels.
Irrespective of glycaemic control, failure to intensify 
anti-hyperglycaemic treatments was associated with 
42% (HR CI: 1.21, 1.66) and 48% (HR CI: 1.36, 1.61) sig-
nificantly increased risk of CVE among patients with 
and without the history of cardiovascular diseases, 
respectively.
Subgroup analyses with adjustments for available 
data on BMI, systolic blood pressure, LDL-cholesterol 
and total cholesterol at diagnosis revealed similar risks 
on cardiovascular outcomes, associated with clinical 
inertia.
Additional analyses on the effects of glycaemic burden
Among patients receiving IT before 12  months, 
those with HbA1c above 7% (53  mmol/mol) and 7.5% 
(58  mmol/mol) during 1  year post diagnosis had signif-
icantly increased risk of any CVE by 24% (HR CI: 1.11, 
1.40) and 33% (HR CI: 1.19, 1.50), respectively compared 
to those with HbA1c below 7% (53 mmol/mol) and 7.5% 
(58 mmol/mol) (Table 3). These patients also had signifi-
cantly increased risks for MI, HF and stroke. Irrespective 
of the intensity of anti-diabetes drugs and the history 
of CVD, patients with HbA1c above 7% (53 mmol/mol) 
consistently over 1 year post diagnosis had 21% (HR CI: 
1.15, 1.28; p  <  0.01) increased risk of composite CVE. 
Among patients without history of CVD, HbA1c above 
7% (53  mmol/mol) was associated with 22% increased 
risk for CVE (HR CI: 1.14, 1.29; p < 0.01).
Male patients, current smokers, and patients who 
developed renal disease during follow-up had 12, 51, 
and 43% increased risk of composite CVE (all p < 0.01), 
respectively.
Discussion
Our population level study, based on more than 100,000 
newly diagnosed T2DM patients with median 5.3  years 
of follow-up, reveals that (1) 26% of patients with HbA1c 
above 7% (53  mmol/mol) during 2  years post diagno-
sis of diabetes did not receive any intensified treatment 
for hyperglycaemia during follow-up, (2) 32 and 46% of 
patients receiving early treatment intensification within 
6 and 12  months of diagnosis continued to have poor 
glycaemic control over 2  years post diagnosis [HbA1c 
above 7.5% (58  mmol/mol)], (3) a 1  year delay in treat-
ment intensification in conjunction with poor glycaemic 
control significantly increased the risks of HF, stroke and 
composite CVE in patients with and without history of 
CVD before diagnosis of diabetes, and (4) irrespective 
of early treatment intensification, the glycaemic burden 
was significantly associated with increased risk of MI, HF, 
stroke and composite CVE.
In the study cohort 54% never received any intensified 
treatment, while their average HbA1c level remained 
above 6.5% (48  mmol/mol), but below 7% (53  mmol/
mol), during 2  years post diagnosis (Fig.  1a). In the 
“never intensified” group, the proportions of patients 
with HbA1c consistently above 7% (53  mmol/mol) and 
7.5% (58  mmol/mol) during 1/2 years post diagnosis 
were 15/11% and 7/4%, respectively. The median follow-
up time in this group was 4.7 years. The incidence of any 
CVE in this group was 5.5% compared to 8.4% in the IT 
group.
Earlier observational studies have reported about 
3  years of delay in treatment intensification (irrespec-
tive of glucose level) [21], high glycaemic burden [HbA1c 
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>7.5% (>58 mmol/mol)] for over more than 5 years after 
the addition of a multiple OADs and insulin [19, 21, 34, 
35], and that it took several years to add insulin after the 
initiation of 2 OADs [34]. The median (IQR) months 
to treatment intensification in our study was 21 [5, 44], 
which is about 12  months less than that reported by 
Khunti et  al. [21]. However, our results are not directly 
comparable, as the studies were differently designed. In 
our study those who received IT within 6/12  months 
of diagnosis had a significant reduction in HbA1c by 
2.5/2.3% within 6 and 12 months post diagnosis (Fig. 1b). 
Our findings on the failure of intensified treatment to 
maintain HbA1c within a clinically acceptable limit is 
broadly in line with those reported in the large surveys 
conducted in USA and UK [36–39]. However, as no study 
has yet reported the trajectory of HbA1c with treatment 
intensification, our unique findings are not directly com-
parable. The mechanisms of increased risk of macrovas-
cular events with hyperglycaemia are not fully known but 
may include oxidative stress, inflammation and thrombo-
sis [40–42].
The ACCORD study in patients with 10 years of dura-
tion of T2DM could not establish any significant benefit 
of intensified glucose lowering treatment on macrovascu-
lar event during 3.5 years of median follow-up [6]. How-
ever, the meta analyses of four major cardiovascular 
outcome trials in patients with T2DM, including the 
ACCORD trial data, reported a 15–17% risk reduction in 
MI, 15% risk reduction in coronary heart disease and 9% 
risk reduction in major cardiovascular event associated 
Table 3 Hazard ratios (95% CI) associated with delays in treatment intensification by 1 year in interaction with poor gly-
caemic control [HbA1C ≥7% (≥53 mmol/mol) and HbA1C ≥7.5% (≥58 mmol/mol)] consistently during 1 year post diag-
nosis of diabetes for cardiovascular events
The reference group was those with TTIT <12 months and HbA1c <7 or 7.5% (<53 or 58 mmol/mol). A: TTIT <12 months and HbA1c ≥7 or 7.5% (≥53 or 58 mmol/mol), 
B: TTIT ≥12 months and HbA1c ≥7 or 7.5% (≥53 or 58 mmol/mol). Analyses are based on multivariate Cox-regression models, with contrast matrix to evaluate the 
effect of delay in treatment intensification in conjunction higher and lower levels of HbA1c at 7 and 7.5% cut offs (53 and 58 mmol/mol).
Without previous  
CVD HR (95% CI)
P With previous  
CVD HR (95% CI)




 With HbA1C ≥7% (≥53 mmol/mol)
  A: IT within 1 year 1.37 (1.09, 1.72) <0.01 1.21 (0.81, 1.82) 0.36 1.32 (1.08, 1.61) <0.01
  B: IT after 1 year 1.80 (1.45, 2.22) <0.01 1.34 (0.91, 1.96) 0.13 1.67 (1.39, 2.01) <0.01
 With HbA1C ≥7.5% (≥58 mmol/mol)
  A: IT within 1 year 1.59 (1.27, 1.99) <0.01 1.12 (0.73, 1.71) 0.62 1.47 (1.20, 1.79) <0.01
  B: IT after 1 year 1.56 (1.24, 1.97) <0.01 1.42 (0.95, 2.14) 0.09 1.52 (1.24, 1.86) <0.01
HF
 With HbA1C ≥7% (≥53 mmol/mol)
  A: IT within 1 year 1.14 (0.94, 1.40) 0.19 1.52 (1.09, 2.12) 0.015 1.23 (1.04, 1.46) 0.017
  B: IT after 1 year 1.63 (1.36, 1.96) <0.01 1.66 (1.21, 2.27) <0.01 1.64 (1.40, 1.91) <0.01
 With HbA1C ≥7.5% (≥58 mmol/mol)
  A: IT within 1 year 1.32 (1.07, 1.62) <0.01 1.52 (1.08, 2.13) 0.016 1.37 (1.15, 1.63) <0.01
  B: IT after 1 year 1.61 (1.32, 1.97) <0.01 1.50 (1.06, 2.12) 0.021 1.58 (1.33, 1.88) <0.01
Stroke
 With HbA1C ≥7% (≥53 mmol/mol)
  A: IT within 1 year 1.28 (1.03, 1.60) 0.025 1.80 (1.10, 2.95) 0.019 1.36 (1.12, 1.66) <0.01
  B: IT after 1 year 1.50 (1.22, 1.84) <0.01 1.60 (0.98, 2.60) 0.06 1.51 (1.25, 1.83) <0.01
 With HbA1C ≥7.5% (≥58 mmol/mol)
  A: IT within 1 year 1.27 (1.01, 1.59) 0.040 1.89 (1.16, 3.06) 0.010 1.36 (1.11, 1.67) <0.01
  B: IT after 1 year 1.37 (1.09, 1.71) <0.01 1.34 (0.78, 2.30) 0.28 1.36 (1.11, 1.67) <0.01
Any CVE
 With HbA1C ≥7% (≥53 mmol/mol)
  A: IT within 1 year 1.22 (1.07, 1.38) <0.01 1.36 (1.06, 1.74) 0.015 1.24 (1.11, 1.40) <0.01
  B: IT after 1 year 1.64 (1.45, 1.85) <0.01 1.57 (1.25, 1.98) <0.01 1.62 (1.46, 1.80) <0.01
 With HbA1C ≥7.5% (≥58 mmol/mol)
  A: IT within 1 year 1.32 (1.15, 1.50) <0.01 1.40 (1.09, 1.81) <0.01 1.33 (1.19, 1.50) <0.01
  B: IT after 1 year 1.50 (1.32, 1.71) <0.01 1.50 (1.17, 1.94) <0.01 1.50 (1.33, 1.68) <0.01
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with intensive glucose control therapy [9, 43]. While 
the UKPDS trial was based on newly diagnosed diabe-
tes patients, the median duration of diabetes in the par-
ticipants of ACCORD, ADVANCE and VADT trials was 
9  years, and 34% of them had history of major cardio-
vascular disease before randomisation. Findings of our 
study based on a cohort of patients with new diagnosis 
of T2DM is broadly in line with the findings of the meta 
analyses in relation to the beneficial effects of intensified 
glucose lowering treatments on major cardiovascular 
risks. The recent cardiovascular outcome trials in estab-
lished T2DM patients had about 5  years of follow-up 
and do not provide insight into any longer time benefit 
in terms of cardiovascular risk. In our cohort with mini-
mum 5  years of follow-up (n =  47,161) who continued 
to have HbA1c above 7% over 1 year, delay in treatment 
intensification was associated with 65% (95% CI of HR: 
1.49, 1.84) increased risk of CVE—very similar to what 
we observed in the whole cohort with median 5.3 years 
of follow-up.
Although early treatment intensification did not reduce 
the HbA1c below clinically acceptable limit in a signifi-
cant proportion of patients, the residual benefit of inten-
sified treatment on macrovascular risk is considerable. 
Compared to patients with HbA1c <7% (<53 mmol/mol) 
during 1  year post diagnosis, those with HbA1c ≥7% 
(≥53 mmol/mol) and received IT within a year of diagno-
sis had 38% lower risk for any CVE (HR: 1.24) compared 
to those who had delayed treatment intensification (HR: 
1.62, Table 3). Early treatment intensification also showed 
considerable residual benefits on MI, HF and stroke. This 
new finding on the residual benefit of intensive anti-dia-
betes treatment on long-term macrovascular risk, even 
in patients with continued high glycaemic burden, needs 
further evaluations with longer term HbA1c trajectory, 
and other cardiovascular risk factors.
Treatment intensification by insulin and sulfonylurea 
drugs and its association with cardiovascular and mor-
tality risk was recently evaluated by Roumie et  al. [44]. 
Patients who added insulin to the first line metformin 
treatment had 30% significantly higher adjusted risk of 
composite macrovascular events, compared to those 
who intensified the treatment by adding sulfonylurea to 
metformin. In our study about 9% patients received treat-
ment intensification with insulin, and these patients had 
higher HbA1c at diagnosis and during follow-up before 
intensification, as expected. Patients receiving insulin 
treatment are generally at higher risk profile, and the find-
ing from Roumie et al. [44] could be partially attributed 
to this factor. In this study our focus was on glycaemic 
burden and the failure to intensify anti-hyperglycaemic 
treatment when deemed necessary. We do however rec-
ognise the importance of evaluating therapeutic inertia 
in a holistic way including cardiovascular risk burden. In 
our risk analyses, we have adjusted for the use of cardio-
protective medications (including anti-hypertensive and 
lipid lowering drugs) and the risk of renal diseases. We 
also conducted separate analyses adjusting for available 
cardiovascular risk factors (weight, blood pressure and 
cholesterol) in 62,000 patients.
While MI and stroke are relatively well defined hard 
outcomes with acute onset, HF is a disease of slow onset 
which develops over time. This introduces the difficulty 
in defining a correct time of onset, and the likelihood of 
getting HF detected in the setting of primary care data-
base to a great extent depends on medical attention and 
on the number of encounters with general practitioners. 
To account for possible detection bias in this context, 
we conducted additional analyses with HF confirmed by 
electrocardiogram analyses, resulting in similar risk esti-
mates for both events.
Patient-level data from electronic databases present 
challenges in terms of accuracy and completeness of 
the study variables of interest. The limitations of this 
study include: (1) the time to treatment intensifica-
tion was based on the dates of available prescriptions 
longitudinally, with the likelihood of missing data; (2) 
non-availability of adherence data on medications; (3) 
non-availability of prescription on diet and exercise; (4) 
failure to account for the socio-economic status of the 
patients, which may well be associated with poor glycae-
mic control and with an elevated risk of cardiovascular 
diseases; (5) non-availability of complete and reliable data 
on alcohol consumption; (6) non-availability of complete 
and reliable longitudinal data on doses for individual 
medications, (7) non-availability of hospitalisation data 
for MI and stroke, and (8) the potential for residual con-
founding, as common in any clinical epidemiological 
study. Due to lack of data on longitudinal doses of indi-
vidual anti-diabetes medications, we could not consider 
the dose escalation for some anti-diabetes therapies as 
potential treatment intensification. However, these issues 
are unlikely to affect the robustness of the results of this 
study. The large analysis cohort was selected from the 
validated CPRD database should be considered as a rep-
resentative sample, and as such, provides a good picture 
of the state of diabetes control in routine practice. Apart 
from complete data on demographics, we had complete 
data on HbA1c measured within 3-month window of 
diagnosis of diabetes. The 6-monthly follow-up meas-
ures of HbA1c were imputed for only 9% missing cases 
with random missing pattern. Finally, careful design of 
the study by defining sensible exposure time, time line for 
events, and appropriate adjustments for various aspects 
while determining the time-to-events are the primary 
strengths of the study.
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Conclusions
As with all observational studies, we were unable to 
provide definitive evidence for direct cause–effect rela-
tionships, and the risks of false positive or negative 
findings due to selection bias and residual confounding, 
even after the most stringent corrections, may not be 
trivial. However, although the results from large con-
trolled clinical trials evaluating the effect of intensified 
glucose lowering treatment on macrovascular compli-
cations in patients with T2DM have been inconclusive, 
our longitudinal study with primary care level data 
demonstrates the beneficial effect of guideline recom-
mended tight glycaemic targets on long-term cardio-
vascular risks.
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